| Project/Area Number |
18K07063
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 49030:Experimental pathology-related
|
|---|
| Research Institution | Tokyo Medical and Dental University |
|---|
Principal Investigator |
Yamamoto Kouhei 東京医科歯科大学, 大学院医歯学総合研究科, 助教 (50451927)
|
|---|
| Project Period (FY) |
2018-04-01 – 2021-03-31
|
| Project Status |
Completed (Fiscal Year 2020)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2020: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2019: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2018: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | がん / 酸化ストレス / セレノプロテイン / SECIS配列 / SECISBP2 / 治療戦略 / 脂質 / 細胞死 / 悪性リンパ腫 / GPX4 |
|---|
| Outline of Final Research Achievements |
proliferation was significantly reduced, and responsiveness to cell death stimuli was increased. Clinicopathological studies suggest that SECISBP2 is an independent prognostic predictor of DLBCL. In vitro, the protein levels of GPX4 and TXNRD1 were decreased in the SECISBP2-KO strain, and cell proliferation was significantly suppressed in the KO strain. Under doxorubicin administration, the SECISBP-KO strain was shown to have a significantly higher mortality. It was suggested that the SECIS sequence and SECISBP2 may be useful as new antitumor targets.
|
| Academic Significance and Societal Importance of the Research Achievements |
難治性の悪性リンパ腫に対して、これまでにない新しい治療戦略を提唱できた点で学術的にも社会的にも大変意義のある研究が遂行されたと考えている。
|
